Developments in the management of advanced soft-tissue sarcoma – olaratumab in context

Lartruvo(®) (olaratumab) is a fully human immunoglobulin G subclass 1 (IgG1) monoclonal antibody that inhibits platelet-derived growth factor receptor alpha (PDGFRα). The antitumor activity of olaratumab has been tested in vitro and in vivo, and inhibition of tumor growth has been observed in cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Moroncini, Gianluca, Maccaroni, Elena, Fiordoliva, Ilaria, Pellei, Chiara, Gabrielli, Armando, Berardi, Rossana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820470/
https://www.ncbi.nlm.nih.gov/pubmed/29497315
http://dx.doi.org/10.2147/OTT.S127609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820470/
https://www.ncbi.nlm.nih.gov/pubmed/29497315
http://dx.doi.org/10.2147/OTT.S127609

Ejemplares similares